{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-258540","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.269065+00:00","generated_at":"2026-05-30T00:31:00.469716+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss","bullets":["Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.","Phase 3 PIVOT-PO trial of tebipenem HBr on track to complete enrollment in 2H 2025 (target ~2,648 patients).","SPR720 program suspended after Phase 2a missed primary endpoint; three cases of reversible grade 3 hepatotoxicity.","Cash and equivalents $76.3M; Oct 2024 restructuring and ~39% RIF extend cash runway into mid-2026.","SPR206 IND cleared for Phase 2 in HABP/VABP, but initiation contingent on non-dilutive funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-258540","json":"https://secwatch.observer/filing/0001193125-24-258540.json","markdown":"https://secwatch.observer/filing/0001193125-24-258540.md","text":"https://secwatch.observer/filing/0001193125-24-258540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/0001193125-24-258540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/d915138d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:31:00.469716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}